Ventricular Arrhythmia Treatment Agent ( Bumac Cab. ), New ACE Inhibitor ( Alphrin Tab. ), Alpha1 - Adrenergic Receptor Selective Blocking Agent ( Minecin Tab. ), Anti - Hypertensive Agent ( Anprasol Inj. ), Migraine Attack & Vertigo Therapeutic Agent ( Headache Cap. )

Product ID: P07

Send Inquiry
Specifications
  • Ventricular arrhythmia treatment agent (bumac cab.):
    • 1 Cab.
    • Mexiletine.HCI: 100mg
    • 500Cab.
    • 226/C
  • New ACE inhibitor (alphrin Tab.):
    • 1 Tab.
    • Enalapri maleate: 10mg
    • 100Tab.; 500Tab.
    • 728/T
  • Alpha1-adrenergic receptor selective blocking agent (minecin Tab.):
    • 1 Tab.
    • Prazocin.HCI: 1mg
    • 500Tab.
    • 44/T
  • Anti-hypertensive agent (anprasol inj.):
    • 1Amp. (1ml)
    • Hydralazine.HCI: 20mg
    • 1ml x 10Amp.
    • 1,608/A
  • Migraine attack & vertigo therapeutic agent (headache cap.)
    • 1 Cap.
    • Flnarizine.HCI: 5.9mg
    • 300Cap.
    • 384/C
Features
  • Ventricular arrhythmia treatment agent (bumac cab.): Na-channel blacker inhibition of permture ventricular contraction and ventricular ectopy.
  • New ACE inhibitor (alphrin Tab.): Hypertension, cardiac failure.
  • Alpha1-adrenergic receptor selective blocking agent (minecin Tab.): Hypertension, congestive heart failure, ect.
  • Anti-hypertensive agent (anprasol inj.): Hypertensive crises.
  • Migraine attack & vertigo therapeutic agent (headache cap.): Intractable migraine, vestibular vertigo.

Main Products

pharmaceuticals, raw - materials